Analysis of FLT-PET imaging as a predictor of hematologic toxicity of chemotherapy in patients with lung cancer

Analysis of FLT-PET imaging as a predictor of hematologic toxicity of chemotherapy in patients with lung cancer - FLT-PET imaging as a predictor of hematologic toxicity

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027540

Enrollment

Registered

2017-05-31

Start date

2010-06-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary lung cancer

Interventions

All patients undergo FLT-PET/MRI before initiation of systemic chemotherapy.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with previously untreated advanced lung cancer 2) Patients who have indication of platinum-based doublet chemotherapy 3) Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 4) Written informed consent

Exclusion criteria

Exclusion criteria: 1) Pregnant woman 2) Patients with metalic device in their body 3) Patients with claustrophobia 4) Other cases attending physician it is determined unsuitable for registration of the study

Design outcomes

Primary

Measure	Time frame
Relationship between FLT uptake of the vertebral body and severe hematologic toxities during platinum doublet chemotherapy.	—

Secondary

Measure	Time frame
1, Relationship between FLT uptake of the vertebral body and severe non-hematologic toxities during platinum doublet chemotherapy. 2, Relationship between FLT uptake of the vertebral body and progression-free survival and overall survival.	—

Countries

Japan

Contacts

Public ContactYukihiro Umeda

University of Fukui Third department of internal medicine

umeda@u-fukui.ac.jp0776-61-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026